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Introduction 
Status epilepticus (SE) carries a risk of major morbidity or mortality (Lowenstein 
and Alldredge, 1998; Rossetti and Lowenstein, 2011). There are many 
treatments for SE, including benzodiazepines such as diazepam (DZP) and 
lorazepam (Meierkord et al., 2006, 2010; Brophy et al., 2012). However, 30–
43% of SE cases become refractory to drugs (Holtkamp et al., 2005; Mayer et 
al., 2002). Prolonged seizure results in neuronal injury, neuronal death, and 
alteration of neuronal networks that can result in death or spontaneous 
recurrent seizures (SRS) and cognitive impairment that will impact the patient’s 
whole life (Curia et al, 2014; Trinka et al., 2015). Many approved antiepileptic 
drugs (AEDs) have been examined in various animal models of SE, some of 
them showed that DZP can terminate seizure (Eslami et al., 2016; Imran et al., 
2015; Suchomelova et al., 2006). However, there still few AEDs that produce 
complete and immediate termination of prolonged seizures (Rossetti and 
Lowenstein, 2011; Löscher and Brandt, 2010). This suggests a need for AEDs 
with novel mechanisms to treat drug-resistant SE.  
Alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor 
antagonists act as broad-spectrum anticonvulsants in animal seizure models 
(Rogawski and Donevan, 1999). Continuous infusion of NS1209 and repeated 
injection of GYKI52466 each terminated prolonged seizures in animal models of 
SE (Pitkänen et al., 2007; Fritsch et al., 2010). However, neither drug alone was 
able to stop seizures with a single dose. Perampanel (PER), a noncompetitive 
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AMPA receptor antagonist, is currently approved for the adjunctive treatment of 
partial-onset seizures, with or without secondary generalized seizures, and for 
primary generalized tonic-clonic seizure in patients 12 years and older. In a 
previous report, a single PER treatment terminated DZP-resistant SE on 
electroencephalography (EEG) when given 30 minutes after SE initiation 
(Hanada et al., 2014). This result suggests that PER has a higher potential for 
suppressing refractory SE than other AEDs and other investigational AMPA 
antagonists.  
Neuronal damage is as important as seizure duration when considering the 
prognosis of refractory SE, but AEDs used in clinical practice have shown 
limited effects on reducing neuronal damage in preclinical models (Löscher and 
Brandt, 2010). NS1209 exerted only mild neuroprotective effects, and no 
pathological analysis has been performed for GYKI52466 (Pitkänen et al., 2007; 
Fritsch et al., 2010). The efficacy of PER has only been demonstrated with EEG 
changes (Hanada et al., 2014), and its impact on neuronal injury has not been 
explored. The lithium-pilocarpine rat model is known to reproduce clinical and 
neuropathological features of human SE (Dubé et al., 2006; Clifford et al., 1987; 
Turski et al., 1989; Curia et al., 2014). In this model, administration of lithium 
and pilocarpine causes SE, which leads to severe neuronal damage mainly in 
the hippocampus, piriform cortex, entorhinal cortex, amygdala, and thalamus 
(Clifford et al., 1987).  
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Purpose 
In this study, we examined whether PER has neuroprotective effects in brain 
areas that can be severely damaged by SE: the CA1 subregion of the 
hippocampus, the piriform cortex (Pir), and the mediodorsal thalamus (MD). We 
also examined the relationship between neuroprotection and seizure 
suppression.
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Materials and Methods 
1 Animals 
Male Sprague Dawley rats (6 weeks old) were purchased from Charles River 
Laboratories Japan, Inc. (Kanagawa, Japan). The rats were housed with 
artificial lighting of 12 hours light (7 a.m. to 7 p.m.), 12 hours dark. Rats were 
provided with pellet food (MF, Oriental Yeast Co., Japan) and tap water ad 
libitum. All procedures were performed in the animal facility accredited by the 
Center for Accreditation of Laboratory Animal Care and use Japan Health 
Sciences Foundation. All protocols were approved by the Institutional Animal 
Care and Use Committee and carried out according to the Eisai Animal 
Experimentation Regulations.   
 
2 Induction of SE and treatment protocol 
SE was induced by the administration of lithium chloride (Wako Pure Chemical 
Industries, Japan) (3 mEq/kg, i.p.), followed 18–24 hours later by scopolamine 
methyl bromide (Sigma-Aldrich, Japan) (5 mg/kg, i.p.) and pilocarpine (Wako 
Pure Chemical Industries, Japan) (30 mg/kg, i.p.) (Curia et al., 2008). The test 
drugs, PER (Eisai Co., Ltd, Kashima, Japan) and DZP (Wako Pure Chemical 
Industries, Japan), were diluted with a vehicle consisting of distilled water, 
dimethyl sulfoxide, and polyethylene glycol 300, at 1:1:1 (v/v). In accordance 
with a previous study (Hanada et al., 2014), three doses of PER were used: 0.6 
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mg/kg (n = 15), 2 mg/kg (n = 15), or 6 mg/kg (n = 8). In the present study, DZP 
rather than vehicle was used as the control to reduce mortality. PER or DZP 10 
mg/kg (n = 6) were administered (i.v.) 30 min after the initiation of SE, which 
was defined as continuous seizures with rearing accompanied by bilateral 
forelimb clonus (Racine score 4; Racine, 1972). The latency to SE initiation was 
evaluated in all rats and analyzed by group, in accordance with a previous study 
(Lucchi et al., 2013). A treatment-naive group (n = 9) of rats not administered 
lithium chloride and pilocarpine to induce seizure was also included. 
 
3 Behavioral observation  
Seizure was classified in accordance with the Racine score (Racine, 1972) as 
follows: score 0 – no seizure behavior; score 1 – immobility, eye closure, 
twitching of vibrissae, sniffing, facial clonus; score 2 – head nodding associated 
with more severe facial clonus; score 3 – clonus of one forelimb; score 4 – 
rearing, often accompanied by bilateral forelimb clonus; score 5 – score 4 with 
loss of balance and falling, accompanied by generalized clonic seizures. The 
efficacy of drugs on seizure suppression was evaluated by using the Racine 
score 30 min after drug administration. 
 
4 Immunohistochemical procedure 
Animals were deeply anesthetized one week after SE induction and perfused 
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with saline, followed by 4% paraformaldehyde in 0.1 M phosphate-buffered 
saline (PBS) (pH 7.0). The brains were removed, post-fixed with 4% 
paraformaldehyde in PBS, and cryoprotected with 30% sucrose in PBS. Frozen 
sections were cut at 30 μm and stored in 0.05% NaN3 in PBS. Slices taken from 
–3.8 mm relative to bregma were used for immunostaining. These selected 
floating sections were stained with anti-neuronal nuclei (NeuN) antibody (1:500, 
Chemicon International, Inc., USA), which was used to determine neuronal loss 
in CA1, Pir, and MD. Secondary antibody was Biotinylated horse anti-mouse 
IgG (1:200, Vector Laboratories, USA). It was followed by the addition of avidin-
biotin-peroxidase complex (VECTASTAIN Elite ABC HRP Kit, Vector 
Laboratories, USA). The peroxidase was then developed by the 
diaminobenzidine (DAB reagent, Vector Laboratories, USA). 
 
5 Quantification of NeuN expression 
Slides in each group were scanned (Aperio Technologies, USA), and the NeuN-
positive cells were detected with a positive pixel-count algorithm (ImageScope, 
Aperio Technologies, Inc., USA) that quantifies the amount of a specific stain 
(Liu et al., 2008). In this algorithm, the brown color of DAB on images of the 
tissues was identified as being weakly positive, positive, or strongly positive. For 
pixels that meet the color specification, the algorithm counted the number in 
each intensity range. In the present study, the whole CA1, Pir, and MD regions 
were analyzed, and the pixels with positive or strongly positive intensity were 
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counted. The average pixel counts of each group across all sections were 
calculated. All of these analyses were performed by an investigator blinded to 
the treatment groups. Samples were photographed with a fluorescence 
microscope (BZ-X700 / BZ-710, KEYENCE, Japan) for expressing the images 
of each treatment group. 
 
6 Statistical analysis 
The survival rate was analyzed with Fisher's exact test. The latency to SE 
initiation was analyzed with one-way analysis of variance (ANOVA), followed by 
Dunnett’s multiple comparison tests. Seizure score was analyzed with one-way 
ANOVA with Dunn’s multiple comparison tests. The percentage of pixel counts 
was compared between the naive and DZP group with Student’s t test, and 
between the DZP group and the groups given different doses of PER with one-
way ANOVA with Dunnett’s multiple comparison tests. The correlation of SE 
seizure suppression effects and neuroprotective effects was analyzed with 
Pearson's correlation coefficient analysis. GraphPad Prism software (Version. 
6.07, GraphPad Software, Inc., USA) was used for all statistical analysis. The 
graphs of correlation were drawn with JMP software (Version. 12.2.0, SAS 
Institute Inc., USA). The level of significance was set to p < 0.05.  
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Results 
1 Survival rate 
All animals given 10 mg/kg DZP survived. PER dose-dependently increased the 
survival rate from 40% in animals given 0.6 mg/kg which was significantly lower 
than in the naïve group, to 100% in animals given 2 or 6 mg/kg PER.  
 
2 Effects of DZP and PER on seizure in lithium-pilocarpine-induced SE 
The latencies to SE initiation were not different among the groups administered 
DZP and PER (Supplementary Table 1). All the animals in the group 
administered DZP (n = 6) showed a Racine score of 5 (Fig. 1). In contrast, 
administration of 6 mg/kg PER terminated seizures in all animals (n = 8). 
Seizures were terminated in 7 of 15 (47%) of the animals in the group given 2 
mg/kg PER. Seizure severity was suppressed to a Racine score < 2 in 75% 
(6/8) of the remaining animals in this group. At a dose of 0.6 mg/kg, PER did not 
suppress seizures, and all 6 animals in this group had Racine scores of 5, as 
was seen in the DZP group (Fig. 1). 
 
3 Effects of DZP and PER on neuronal loss in animals following lithium-
pilocarpine-induced SE 
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The DZP-treated group exhibited more extensive neuronal loss in CA1, Pir, and 
MD than the naive group (Fig. 2, A–F). Pixel counts of the naive group in each 
area were set to 100%. The DZP-treated animals exhibited a significant 
reduction of pixel counts to 22.2%, 8.5%, and 23.2% of the naive values in CA1, 
Pir, and MD, respectively (Fig. 3, A, C, E). The most severe neuronal loss was 
observed in the Pir area. In contrast, PER dose-dependently prevented 
neuronal loss, and at higher doses the pixel counts, representing the level of 
preserved neurons, were comparable to those in the naive group (Fig. 2, G–R; 
Fig. 3, A, C, E).  
In the group treated with 6 mg/kg PER, neurons were preserved in CA1, Pir, 
and MD (Fig. 2, P–R) at 105.3%, 111.7%, and 92.4%, respectively, of the levels 
in the naive group (Fig. 3, A, C, E). These levels were significantly higher than 
those in the DZP-treated group. 
In rats treated with 2 mg/kg PER, the pixel counts in CA1, Pir, and MD were 
83.9%, 90.0%, and 92.4%, respectively, of the counts in naive rats (Fig. 3, A, C, 
E). The rats in this group were divided into two subgroups for analysis: one in 
which the seizures were continued and one in which the seizures were 
terminated. The seizure-free group exhibited nearly the same pixel counts as 
the naive group: 101.7%, 102.7%, and 90.3% of naive group in CA1, Pir, and 
MD, respectively (Fig. 3, B, D, F). All three of the values were significantly 
higher than the corresponding values in the DZP-treated group (Fig. 2, M–O; 
Fig. 3, B, D, F).  
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Even in the group with continued seizures, PER provided more neuroprotective 
effects than DZP (Fig. 2, J–L). The pixel counts in CA1, Pir, and MD were 
68.4%, 78.8%, and 94.3% of those in the naive animals, respectively (Fig.3, B, 
D, F).  
In rats treated with 0.6 mg/kg PER, the pixel counts in CA1, Pir, and MD were 
45.2%, 40.6%, and 38.0%, respectively, of the counts in naive rats (Fig. 3, A, C, 
E). These values were not significantly different from those in the DZP-treated 
group.  
To analyze the correlation between seizure suppression and neuroprotective 
effect, pixel counts were plotted against seizure score (Fig. 4). The 
neuroprotective effect was significantly inversely correlated with seizure score, 
with Pearson's r values of –0.72 for CA1, –0.68 for Pir, and –0.52 for MD (Fig. 4 
A–C).  
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Discussion 
In the present study, PER potently suppressed seizures and prevented 
neuronal loss in DZP-resistant SE. DZP is used for SE management clinically, 
but its ability to suppress seizures typically declines when the duration of SE 
increases. The mechanism of this decline has been reported to be the 
functional loss of postsynaptic GABAA receptors (Naylor et al., 2005; Goodkin 
et al., 2005, 2008). In this study, DZP neither terminated seizures nor prevented 
neuronal degeneration. In the lithium-pilocarpine SE model, seizure is initiated 
by the activation of the cholinergic system, whereas the continuation of seizure 
activity is thought to occur via a glutamatergic mechanism (Clifford et al., 1987). 
It has also been reported that AMPA-mediated neuronal transmission is 
preserved in the lithium-pilocarpine model (Chen et al., 2007). These reports 
could explain the potent effect of PER on both seizure and neurodegeneration 
in DZP-resistant prolonged SE. 
A neuroprotective effect of PER was observed in all three of the analyzed brain 
areas. Neuronal survival was correlated with seizure score at evaluation, which 
is consistent with a previous report (Gorter et al., 2003) and supports the 
importance of early seizure termination for preventing neuronal injury. Although 
we did not monitor the seizure over time until sacrifice in the present study, our 
preliminary data (not shown) suggested than seizures did not recur in the PER 
administered group until five hours after treatment. This would also contribute to 
the neuroprotective effect. Several reports suggest that the neuronal loss in SE 
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occurs secondary to seizure and that AMPA receptors are involved in these 
sequential actions. Continuous seizure results in excessive neuronal excitability 
due to significant elevations in extracellular glutamate (Wasterlain et al., 1993; 
Heinemann et al., 2002a, 2002b). The increased glutamate causes excessive 
stimulation of postsynaptic glutamate receptors and overload of Ca2+, leading to 
neuronal death (Choi, 1988). The Ca2+ overload occurs in part because AMPA 
receptors change from Ca2+ impermeable to Ca2+ permeable in the presence of 
increased glutamate (Rajasekaran et al., 2012; Grooms et al., 2000), and the 
increased Ca2+ influx through AMPA receptors can cause cell death (Pellegrini-
Giampietro et al., 1997). PER can inhibit both Ca2+-permeable and Ca2+-
impermeable AMPA receptors (Barygin, 2016). Efficient inhibition of Ca2+-
permeable receptors by PER might prevent neuronal damage in rats with 
severe seizures.  
The potent effects of a single dose of PER on both SE termination and 
prevention of neuronal loss have not been observed even with other AMPA 
receptor antagonists. We administered the drugs 30 minutes after SE onset, 
when the glutamate level would have been high. A competitive AMPA receptor 
antagonist such as NS1209 might be displaced by high agonist concentrations 
(Kenakin, T., 2006), possibly explaining why NS1209 must be given as a 
continuous infusion and has limited effects (Pitkänen et al., 2007). Non-
competitive receptor antagonists as PER and GYKI52466 are thought to confer 
‘insurmountable’ blockade of receptors, maintaining antagonism despite high 
agonist concentrations (high glutamate levels in SE). This constant blockade 
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may enhance the effects in drug resistant SE. However, because GYKI52466 
was tested via two intraperitoneal bolus injections given 15 minutes apart which 
was not meant to terminate SE immediately, it is not clear whether it could exert 
the same neuroprotective effect as PER (Fritsch et al., 2010). 
Neuronal loss in the lithium pilocarpine model has also been reported to 
resemble that from ischemic injury (Lucchi et al., 2013; Curia et al., 2014). Both 
DZP (Schwartz et al., 1995) and PER (Niu et al., 2017) protect against neuronal 
loss in ischemic lesions. Because the synaptic and cellular events caused by 
brain ischemia are similar to those induced by epilepsy, the neuroprotective 
effect of PER against ischemic lesions shown in a previous study (Calabresi et 
al., 2003) may demonstrate the potent effects in SE from diverse aspects. 
The level of neuroprotection provided by PER varied by region in the treated 
rats whose seizures continued. The remaining seizures in rats treated with 2 
mg/kg PER were under Racine score 2 and were accompanied by partial 
attenuation of neuronal loss in CA1 and Pir and full prevention of neuronal loss 
in MD (Fig. 3). In fact, there was no correlation between the intensities of 
preserved neurons in CA1 and MD (data not shown), suggesting that the 
neuroprotective effects of PER on MD and CA1 are independent. The regional 
differences in neuroprotective effects might reflect different levels of seizure 
suppression; that is, PER may have suppressed seizure more fully in MD than 
in CA1 and Pir. The seizure-induced intracellular Ca2+ concentration is much 
higher in MD than in dorsal CA1 and Pir in adult rats with SE (Friedman et al., 
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2008). Because the degree of Ca2+ influx contributes to the level of neuronal 
injury (Delorenzo et al., 2005), neurons in MD may be highly susceptible to 
neurodegeneration. PER, however, more strongly prevented neuronal loss in 
MD than in CA1 and Pir. The hippocampus and Pir are essential areas for the 
initiation of limbic seizures (Turski et al.,1983), whereas MD receives inputs 
from these limbic areas and is essential for propagating seizures that originate 
there (Tortorella et al., 1997; Cassidy and Gale, 1998; Rogawski, 2013; Bertram 
et al., 2001, 2008). Thus, greater seizure suppression in MD than in the 
hippocampus and Pir implies that PER had more effect on seizure propagation 
than on the initiation of SE. This hypothesis is supported by the report of 
Cassidy and Gale (1998), which suggests that MD is required for the further 
development of seizures initiated in the limbic system, and this excitatory 
transmission is primarily glutamatergic. Moreover, the thalamus contains 
abundant AMPA receptors that are important for mediating seizure propagation 
(Rogawski, 2013). Taken together, all of these findings support our conclusion 
that PER suppressed seizures by acting on AMPA receptors, which contribute 
to seizure development in SE. That may explain why PER confers greater 
seizure control in patients with secondary generalization and primary 
generalized tonic-clonic seizure in clinical use (Steinhoff et al., 2013; French at 
al., 2015).  
Neuronal loss in hippocampus and thalamus has resulted in severe postictal 
cognitive dysfunction and the appearance of later SRS in both SE models and 
patients with SE (de Oliveira et al., 2008; Cassidy and Gale, 1998; 
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Helmstaedter, 2007; Sheppard and Lippé, 2012; Curia et al., 2008; Klitgaard et 
al., 2002; Trinka et al., 2015). Prevention of neuronal loss in these areas 
prevented later cognitive dysfunction and the appearance of SRS (Cunha et al., 
2009; Yang et al., 2009; Brandt et al., 2015). In this study, we demonstrated 
that PER has a strong ability to terminate seizures and a clear neuroprotective 
effect in the lithium-pilocarpine rat model. However, we have not evaluated 
long-term behavioral changes after SE. The effect of PER on SRS development 
and various neurological deficits, including cognitive dysfunction, should be 
studied. 
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Conclusion 
The administration of PER to rats experiencing DZP-resistant SE significantly 
protected multiple key brain areas from neuronal loss by terminating the 
seizures. The neuroprotective effects of PER were more potent in a region 
associated with the generalization of limbic seizures, MD, than in CA1 or Pir, 
which are associated with seizure initiation. These results suggest that the 
suppression of seizure generalization might be a characteristic property of PER.   
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Figures: 
Figure. 1 
 
Fig. 1. Effects of perampanel (PER) and diazepam (DZP) on lithium-pilocarpine-
induced seizures. DZP, n = 6; PER 0.6 mg/kg, n = 6; PER 2 mg/kg, n = 15; PER 
6 mg/kg, n = 8. * p < 0.05, versus the DZP-treated group. 
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Figure. 2 
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Fig. 2. Photomicrographic images of CA1 (left), piriform cortex (middle), and 
mediodorsal thalamus (right) in diazepam (DZP)- or perampanel (PER)-treated 
rats. The staining was defined as weakly positive, positive, or strongly positive 
on the basis of the color intensity, and the pixels in the positive and strongly 
positive categories were counted. Seizure (+), seizures continued after 
treatment; seizure (-), seizures terminated after treatment. Scale bar, 300 µm. 
Asterisks show the area of neuronal loss in piriform cortex and mediodorsal 
thalamus. Arrows indicate the area of neuronal loss in CA1. 
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Figure. 3 
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Fig. 3. Effects of diazepam (DZP) and perampanel (PER) on neuronal survival 
one week after SE initiation. Data are shown relative to the pixel counts for the 
naive group, which were set at 100%. The error bars represent the standard 
error of the mean. (A) and (B) are from the CA1 subregion of the hippocampus, 
average pixel counts of naïve group was 146,013; (C) and (D) are from the 
piriform cortex, average pixel counts of naïve group was 479,352; (E) and (F) 
are from the mediodorsal thalamic nucleus, average pixel counts of naïve group 
was 430,930. n = 6–15. * p < 0.05 versus the naive group. # p < 0.05 versus the 
DZP-treated group. (B), (E), and (F) showed the level of neuronal survival in the 
subgroups of 2 mg/kg of PER which are seizure sustained group [seizure (+), n 
= 8]) and seizure free group [seizure (-), n = 7]. 
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Figure. 4 
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Fig. 4. The correlation of seizure score and the neuroprotective effect of 
perampanel (PER). The Pearson's r value was –0.72 in the CA1 subregion (A, p 
< 0.05), –0.68 in the piriform cortex (B, p < 0.05), and –0.52 in the mediodorsal 
thalamic nucleus (C, p < 0.05). 
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Supplementary file: 
Supplementary table. 1 
 
Latency to lithium-pilocarpine induced SE initiation
DZP
(mg/kg) 10 0.6 2 6
38.9±3.50 35.3±4.56 36.3±2.74 41.8±3.92
PER
Latency to SE
initiation (min)
Latency to lithium-pilocarpine induced SE initiation were not different among the
various treatment groups (P>0.05; one-way ANOVA).
